Epilepsy & Seizures

Filter Your Results

 

News

 

Advisory Committee Supports Approval of Oral Cannabidiol for Dravet Syndrome and Lennox-Gastaut Syndrome

Thursday, April 19, 2018—The Peripheral and Central Nervous System Drugs Advisory Committee of the Food and Drug Administration (FDA) unanimously recommended supporting the approval of the investigati…

Everolimus Approved as Adjunctive Treatment for Tuberous Sclerosis-Associated Partial-Onset Seizures

Wednesday, April 11, 2018—The Food and Drug Administration (FDA) has granted approval for the use of everolimus (Afinitor DISPERZ; Novartis, East Hanover, NJ) to treat tuberous sclerosis complex (TSC)-…

Approval Sought for use of Perampanel in Pediatric Patients With Epilepsy

Friday, March 30, 2018—A supplemental new drug application (sNDA) has been submitted seeking priority review for the use of perampanel (CIII) (FYCOMPA; Eisai Inc, Woodcliff Lake, NJ) for specif…

New Therapeutic Candidates Identified for SCN8A-Related Epilepsy

Monday, March 26, 2018—Caused by a gain-of-function mutation in the SCN8A gene encoding the Nav1.6 sodium channel, SCN8A-related epilepsy is characterized by developmental delay, seizure onset in in…

Seizures and Epilepsy in the Elderly

Rani A. Sarkis, MD, MSC; and Matthew Schrettner, MD

March/April 2018—A focus on multidisciplinary care.

Results From Cannabidiol Dose-Ranging Safety Trial for Treating Patients With Dravet Syndrome

Wednesday, March 14, 2018—Previous randomized controlled trials have suggested that orally administered cannabidiol (CBD) is effective as an add-on to existing antiepileptic drugs (AEDs) for the treatm…

Pediatricians, Pediatric Neurologists, Patient Advocates, and Industry Partner to Create High-Tech Risk-Screening Tool for Children with Epilepsy

Tuesday, February 13, 2018—Digital Health Solutions (DHS), the Child Neurology Foundation (CNF), and Greenwich Biosciences began a collaborative effort to develop a digital tool that will prompt provide…

Food and Drug Administration Grants Breakthrough Therapy Designation for ZX008 for Treatment of Dravet Syndrome

Tuesday, February 06, 2018—Low-dose fenfluramine (ZX008, Zogenix) is classified as an orphan drug for the treatment of two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. Positive r…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC